+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Glomerulonephritis - Pipeline Review, H1 2020

  • ID: 5017467
  • Drug Pipelines
  • March 2020
  • Region: Global
  • 303 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Aduro BioTech Inc
  • Bristol-Myers Squibb Co
  • Cytodesign Inc
  • Integral Molecular Inc
  • MorphoSys AG
  • Pfizer Inc
  • MORE
Glomerulonephritis - Pipeline Review, H1 2020

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Glomerulonephritis - Pipeline Review, H1 2020, provides an overview of the Glomerulonephritis (Genito Urinary System And Sex Hormones) pipeline landscape.

Glomerulonephritis is also known as glomerular nephritis (GN) or glomerular disease. It is a disease of the kidney, characterized by inflammation of the glomeruli. Causes of glomerulonephritis include Streptococcal infection of the throat known as strep throat, immune diseases, such as lupus, Type 1 diabetes and type 2 diabetes and viruses, such as HIV, hepatitis B virus, and hepatitis C virus. Factors that increase chances of getting glomerulonephritis include family history of glomerulonephritis, the presence of a known cause of glomerulonephritis and high blood pressure. Common symptoms of glomerulonephritis are blood in the urine (dark, rust-colored, or brown urine), foamy urine, swelling (edema) of the face, eyes, ankles, feet, legs, or abdomen. Treatment will depend on the cause of glomerulonephritis such as medications, lifestyle changes, dialysis and transplant.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Glomerulonephritis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Glomerulonephritis (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Glomerulonephritis (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Glomerulonephritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 4, 19, 11, 19, 4 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.

Glomerulonephritis (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Glomerulonephritis (Genito Urinary System And Sex Hormones).
  • The pipeline guide reviews pipeline therapeutics for Glomerulonephritis (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Glomerulonephritis (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Glomerulonephritis (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Glomerulonephritis (Genito Urinary System And Sex Hormones)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Glomerulonephritis (Genito Urinary System And Sex Hormones).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Glomerulonephritis (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Aduro BioTech Inc
  • Bristol-Myers Squibb Co
  • Cytodesign Inc
  • Integral Molecular Inc
  • MorphoSys AG
  • Pfizer Inc
  • MORE
  • Introduction
  • Glomerulonephritis - Overview
  • Glomerulonephritis - Therapeutics Development
  • Glomerulonephritis - Therapeutics Assessment
  • Glomerulonephritis - Companies Involved in Therapeutics Development
  • Glomerulonephritis - Drug Profiles
  • Glomerulonephritis - Dormant Projects
  • Glomerulonephritis - Discontinued Products
  • Glomerulonephritis - Product Development Milestones
  • Appendix
List of Tables
  • Number of Products under Development for Glomerulonephritis, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Glomerulonephritis - Pipeline by Aduro BioTech Inc, H1 2020
  • Glomerulonephritis - Pipeline by Alexion Pharmaceuticals Inc, H1 2020
  • Glomerulonephritis - Pipeline by Algomedix Inc, H1 2020
  • Glomerulonephritis - Pipeline by Alnylam Pharmaceuticals Inc, H1 2020
  • Glomerulonephritis - Pipeline by Amyndas Pharmaceuticals LLC, H1 2020
  • Glomerulonephritis - Pipeline by Angion Biomedica Corp, H1 2020
  • Glomerulonephritis - Pipeline by Apellis Pharmaceuticals Inc, H1 2020
  • Glomerulonephritis - Pipeline by Aravive Inc, H1 2020
  • Glomerulonephritis - Pipeline by Aurinia Pharmaceuticals Inc, H1 2020
  • Glomerulonephritis - Pipeline by Biogen Inc, H1 2020
  • Glomerulonephritis - Pipeline by Bristol-Myers Squibb Co, H1 2020
  • Glomerulonephritis - Dormant Projects, H1 2020
  • Glomerulonephritis - Dormant Projects, H1 2020 (Contd..1), H1 2020
  • Glomerulonephritis - Discontinued Products, H1 2020
List of Figures
  • Number of Products under Development for Glomerulonephritis, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Top 10 Molecule Types, H1 2020
  • Number of Products by Stage and Top 10 Molecule Types, H1 2020
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Aduro BioTech Inc
  • Alexion Pharmaceuticals Inc
  • Algomedix Inc
  • Alnylam Pharmaceuticals Inc
  • Amyndas Pharmaceuticals LLC
  • Angion Biomedica Corp
  • Apellis Pharmaceuticals Inc
  • Aravive Inc
  • Aurinia Pharmaceuticals Inc
  • Biogen Inc
  • Bristol-Myers Squibb Co
  • Calliditas Therapeutics AB
  • Cellmid Ltd
  • Certa Therapeutics Pty Ltd
  • ChemoCentryx Inc
  • Coegin Pharma AS
  • Complexa Inc
  • Cytodesign Inc
  • Dimerix Ltd
  • Ergon Pharmaceuticals LLC
  • Goldfinch Biopharma Inc
  • HanAll Biopharma Co Ltd
  • Integral Molecular Inc
  • INVENT Pharmaceuticals Inc
  • Ionis Pharmaceuticals Inc
  • Kyowa Kirin Co Ltd
  • Mallinckrodt Plc
  • Merck KGaA
  • MorphoSys AG
  • Novartis AG
  • NovelMed Therapeutics Inc
  • Omeros Corp
  • Oraxion Therapeutics Inc
  • Pfizer Inc
  • Polyneuron Pharmaceuticals AG
  • Ra Pharmaceuticals Inc
  • Reata Pharmaceuticals Inc
  • RemeGen Ltd
  • Retrophin Inc
  • Sujana Biotech, LLC
  • Takeda Pharmaceutical Co Ltd
  • Vertex Pharmaceuticals Inc
  • Visterra Inc
  • ZyVersa Therapeutics Inc
Note: Product cover images may vary from those shown
Adroll
adroll